专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2009089620A8 PROTEIN C RS2069915 AS A RESPONSE PREDICTOR TO SURVIVAL AND ADMINISTRATION OF ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND 审中-公开
标题翻译：蛋白C RS2069915作为活化蛋白C或蛋白C类化合物的生存和施用的反应预测
公开(公告)号：WO2009089620A8
公开(公告)日：2012-04-26
申请号：PCT/CA2009000037
申请日：2009-01-15
申请人： UNIV BRITISH COLUMBIA , SIRIUS GENOMICS INC , WALLEY KEITH R , RUSSELL JAMES A , SIDDIQUI ASIM SAROSH , GORDON ANTHONY , WILLIAMS MARK D , MACIAS WILLIAM L , KIRKWOOD SANDRA CLOSE , LILLY CO ELI
发明人： WALLEY KEITH R , RUSSELL JAMES A , SIDDIQUI ASIM SAROSH , GORDON ANTHONY , WILLIAMS MARK D , MACIAS WILLIAM L , KIRKWOOD SANDRA CLOSE
IPC分类号： C40B40/06 , A61K38/48 , A61K45/00 , C07H21/00 , C12N9/64 , C12N15/57 , C12Q1/68 , C40B30/00 , G06F19/18 , G06F19/24
CPC分类号： A61K31/7088 , A61K38/4866 , A61K45/06 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172 , G06F19/18 , G06F19/24 , Y02A90/26 , A61K2300/00
摘要： Provided herein are methods, oligonucleotides and peptide nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C-like compound or susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. The method generally comprises determining a genotype of said subject at one or more of polymorphic sites in the subject's protein C gene selected from one or more of the following: rs20069915 and one or more polymorphism sites in linkage disequilibrium thereto, selected from one or more of the following: rs2069910; rs2069916; rs2069924; rs2069931; rsl799808; rs2069920; and rs6714364 and may further involve comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response to treatment with activated protein C or protein C-like compound or correspond to susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. Also provided are methods of treating subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：本文提供的方法，寡核苷酸和肽核酸，组合物和试剂盒用于预测受试者对用活化蛋白C或蛋白质C样化合物治疗或对主要器官功能障碍或对炎性病症易感性的敏感性的反应。该方法通常包括在受试者的蛋白C基因中的一个或多个多态性位点确定所述受试者的基因型，所述多态性位点选自以下一个或多个：rs20069915和与其连锁不平衡的一个或多个多态性位点，其选自以下的一个或多个如下：rs2069910; rs2069916; rs2069924; rs2069931; rsl799808; rs2069920; 和rs6714364，并且可以进一步涉及将所确定的基因型与已知的多态性基因型进行比较，所述基因型对应于用活化的蛋白C或蛋白质C样化合物治疗的改善的应答，或对应于对主要器官功能障碍或对炎性病症的易感性的易感性。还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗受试者的方法。

12. 发明申请

WO2009089620A1 PROTEIN C RS2069915 AS A RESPONSE PREDICTOR TO SURVIVAL AND ADMINISTRATION OF ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND 审中-公开
标题翻译：蛋白C RS2069915作为活化蛋白C或蛋白C类化合物的生存和施用的反应预测
公开(公告)号：WO2009089620A1
公开(公告)日：2009-07-23
申请号：PCT/CA2009/000037
申请日：2009-01-15
申请人： THE UNIVERSITYOF BRITISH COLUMBIA , SIRIUS GENOMICS INC. , ELI LILLY AND COMPANY , WALLEY, Keith R. , RUSSELL, James A. , SIDDIQUI, Asim Sarosh , GORDON, Anthony , WILLIAMS, Mark D. , MACIAS, William L. , KIRKWOOD, Sandra Close
发明人： WALLEY, Keith R. , RUSSELL, James A. , SIDDIQUI, Asim Sarosh , GORDON, Anthony , WILLIAMS, Mark D. , MACIAS, William L. , KIRKWOOD, Sandra Close
IPC分类号： C40B40/06 , A61K38/48 , A61K45/00 , C07H21/00 , C12Q1/68 , C40B30/00 , C12N9/64 , C12N15/57 , G06F19/00
CPC分类号： A61K31/7088 , A61K38/4866 , A61K45/06 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172 , G06F19/18 , G06F19/24 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/473 , Y02A50/478 , Y02A90/26 , A61K2300/00
摘要： Provided herein are methods, oligonucleotides and peptide nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C-like compound or susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. The method generally comprises determining a genotype of said subject at one or more of polymorphic sites in the subject's protein C gene selected from one or more of the following: rs20069915 and one or more polymorphism sites in linkage disequilibrium thereto, selected from one or more of the following: rs2069910; rs2069916; rs2069924; rs2069931; rsl799808; rs2069920; and rs6714364 and may further involve comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response to treatment with activated protein C or protein C-like compound or correspond to susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. Also provided are methods of treating subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：本文提供的方法，寡核苷酸和肽核酸，组合物和试剂盒用于预测受试者对用活化蛋白C或蛋白质C样化合物治疗或对主要器官功能障碍或对炎性病症易感性的敏感性的反应。该方法通常包括在受试者的蛋白C基因中的一个或多个多态性位点确定所述受试者的基因型，所述多态性位点选自以下一个或多个：rs20069915和与其连锁不平衡的一个或多个多态性位点，其选自以下的一个或多个如下：rs2069910; rs2069916; rs2069924; rs2069931; rsl799808; rs2069920; 和rs6714364，并且可以进一步涉及将所确定的基因型与已知的多态性基因型进行比较，所述基因型对应于用活化的蛋白C或蛋白质C样化合物治疗的改善的应答，或对应于对主要器官功能障碍或对炎性病症的易感性的易感性。还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗受试者的方法。

13. 发明申请

WO2007140625A1 INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF SUBJECT OUTCOME IN CRITICALLY ILL SUBJECTS 审中-公开
标题翻译：作为主要观察指标的干扰素多态性
公开(公告)号：WO2007140625A1
公开(公告)日：2007-12-13
申请号：PCT/CA2007/001042
申请日：2007-06-11
申请人： THE UNIVERSITY OF BRITISH COLUMBIA , WALLEY, Keith, R. , RUSSELL, James, A. , WATTANATHUM, Anan
发明人： WALLEY, Keith, R. , RUSSELL, James, A. , WATTANATHUM, Anan
IPC分类号： C40B40/06 , A61K38/48 , A61P29/00 , C12Q1/68 , C40B40/14
CPC分类号： C12Q1/6883 , A61K38/4866 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/473 , Y02A50/478
摘要： The invention provides methods, nucleic acids, compositions and kits for predicting a subject's outcome with an inflammatory condition and a subject's response to treatment with activated protein C or protein C like compound to identify subjects having a greater benefit from treatment with activated protein C. The method generally comprises determining a interferon gamma (IFNG) gene polymorphism genotype(s) of a subject for one or more polymorphisms in the IFNG gene or associated sequence, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response polymorphism to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with activated protein C or protein C like compound and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：本发明提供了用活性蛋白C或蛋白C类化合物治疗炎症状况和受试者对治疗反应的方法，核酸，组合物和试剂盒，用于预测受试者的结局，以鉴定用活化蛋白C治疗具有更大益处的受试者。方法通常包括确定受试者在IFNG基因或相关序列中的一个或多个多态性的干扰素γ（IFNG）基因多态性基因型，将确定的基因型与已知基因型与对应于改良的应答多态性的多态性进行比较，鉴定具有更有可能受到活化蛋白C或蛋白C类化合物治疗并随后治疗的炎症状况的潜在受试者从炎症状态恢复。本发明还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗这些受试者的方法。

14. 发明申请

WO2005087789A1 PROTEIN C AND ENDOTHELIAL PROTEIN C RECEPTOR POLYMORPHISMS AS INDICATORS OF SUBJECT OUTCOME 审中-公开
标题翻译：蛋白C和内皮蛋白C受体多态性作为主要观察指标
公开(公告)号：WO2005087789A1
公开(公告)日：2005-09-22
申请号：PCT/CA2005/000409
申请日：2005-03-18
申请人： THE UNIVERSITY OF BRITISH COLUMBIA , RUSSELL, James, A. , WALLEY, Keith, R.
发明人： RUSSELL, James, A. , WALLEY, Keith, R.
IPC分类号： C07H21/00
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
摘要： The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition and for identifying subjects having a greater benefit from treatment with an anti-inflammatory agent or an anti-coagulant agent. The method generally comprises determining a protein C and/or EPCR genotype(s) of a subject for a polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis. The invention also provides for methods of identifying potential subjects having an inflammatory condition who are more likely to benefit from treatment with an anti-inflammatory agent or anti-coagulant agent and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：本发明提供了用于获得具有或处于发展炎症状态的风险的受试者的预后以及用于通过用抗炎剂或抗凝血剂治疗具有更大益处的受试者来获得预后的方法和试剂盒。该方法通常包括确定受试者的蛋白质C和/或EPCR基因型，用于这些基因中的多态性，将确定的基因型与已知基因型与多态性相对应的受试者从炎症中恢复的能力进行比较条件和根据其预后鉴定受试者。本发明还提供了鉴定潜在受试者的方法，所述潜在受试者具有更可能受益于用抗炎剂或抗凝血剂治疗并且随后治疗从炎症状态恢复的炎症状况。本发明还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗这些受试者的方法。

15. 发明申请

WO2004083457A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) HAPLOTYPES USEFUL AS INDICATORS OF PATIENT OUTCOME 审中-公开
标题翻译： PLASMINOGEN ACTIVATOR INHIBITOR-1（PAI-1）HAPLOTYPES有用作为患者观察指标
公开(公告)号：WO2004083457A1
公开(公告)日：2004-09-30
申请号：PCT/CA2004/000424
申请日：2004-03-19
申请人： THE UNIVERSITY OF BRITISH COLUMBIA , RUSSELL, James, A. , WALLEY, Keith, R.
发明人： RUSSELL, James, A. , WALLEY, Keith, R.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a Plasminogen Activator Inhibitor-1 (PAI-1) genotype of a patient for one or more polymorphisms in the PAI-1 gene of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. PAI-1 genotype screening may be useful in identifying patients who would benefit from increased monitoring by healthcare professionals, and/or possible therapeutic intervention, if the patient were to develop inflammation due to systematic inflammation response syndrome (SIRS), bacterial infection, bacteraemia, sepsis, septic shock, organ dysfunction, and trauma. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patients to recover from the inflammatory condition.
摘要翻译：本发明提供了用于获得具有或具有发展炎性病症风险的患者的预后的方法和试剂盒。该方法通常包括确定患者的PAI-1基因中一种或多种多态性的患者的纤溶酶原激活物抑制剂-1（PAI-1）基因型，将确定的基因型与已知基因型与多态性相对应的能力进行比较的患者从炎症状态恢复并根据其预后鉴定患者。如果患者由于系统性炎症反应综合征（SIRS），细菌感染，细菌性贫血引起的炎症，PAI-1基因型筛选可用于鉴定将受益于由医疗保健专业人员进行更多监测的患者和/或可能的治疗性干预，败血症，败血性休克，器官功能障碍和创伤。本发明还提供了鉴定与患者从炎症状态恢复的能力相对应的其他多态性的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式